ARCHIVES

Tyrosine Kinase Inhibitor Encoraging For NSCLC

This article is from The Cancer Letter archive.

Vol. 24 No. 7 | July 27, 2001

Download PDF Visit The Full Archive

Related Articles

Two New Organ Systems Working Groups to Be Considered By NCAB

October 4, 1985

In Brief: FDA Seeks Applicants For Oncology Div. Head; Croce Wins Pasarow Award; CRI Honors Five

August 18, 1995

Support Available For Studies Abroad

August 12, 1983

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

July 27, 2007

Post Starts Series With Horror Stories On Drug Testing; DeVita Says They Are “Slanted, Distorted”

October 23, 1981

Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies.

April 30, 2004